Compounds > 4-dimethylamino-2',4',6'-trimethoxychalcone
Page last updated: 2024-12-11

4-dimethylamino-2',4',6'-trimethoxychalcone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID6386019
CHEMBL ID34446
CHEBI ID191029
SCHEMBL ID19182772

Synonyms (8)

Synonym
CHEMBL34446
CHEBI:191029
(e)-3-[4-(dimethylamino)phenyl]-1-(2,4,6-trimethoxyphenyl)prop-2-en-1-one
4-dimethylamino-2',4',6'-trimethoxychalcone
2-propen-1-one, 3-[4-(dimethylamino)phenyl]-1-(2,4,6-trimethoxyphenyl)-
VPSSTEFJODQSHX-DHZHZOJOSA-N
4-dimethylamino-2',4',6'-trimethoxychalcone, aldrichcpr
SCHEMBL19182772
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic compoundA cyclically conjugated molecular entity with a stability (due to delocalization) significantly greater than that of a hypothetical localized structure (e.g. Kekule structure) is said to possess aromatic character.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID1427258Cytotoxicity against human HCT116 cells assessed as cell survival at 50 uM after 48 hrs by Hoechst 33342 staining based assay relative to control2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Mechanisms of action and structure-activity relationships of cytotoxic flavokawain derivatives.
AID612699Cytotoxicity against african green monkey Vero cells at 50 uM after 72 hrs2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Trimethoxy-chalcone derivatives inhibit growth of Leishmania braziliensis: synthesis, biological evaluation, molecular modeling and structure-activity relationship (SAR).
AID1427262Cytotoxicity against human fibroblasts assessed as cell survival at 50 uM after 48 hrs by Hoechst 33342 staining based assay relative to control2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Mechanisms of action and structure-activity relationships of cytotoxic flavokawain derivatives.
AID1427260Cytotoxicity against human NCI-H727 cells assessed as cell survival at 50 uM after 48 hrs by Hoechst 33342 staining based assay relative to control2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Mechanisms of action and structure-activity relationships of cytotoxic flavokawain derivatives.
AID315123Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Synthesis and pharmacological activity of chalcones derived from 2,4,6-trimethoxyacetophenone in RAW 264.7 cells stimulated by LPS: quantitative structure-activity relationships.
AID89025Inhibition of the production of Interleukin-1-beta from human peripheral blood monocytes stimulated with lipopolysaccharide (LPS) at 10 uM1993Journal of medicinal chemistry, May-14, Volume: 36, Issue:10
2'-substituted chalcone derivatives as inhibitors of interleukin-1 biosynthesis.
AID1427261Cytotoxicity against human HaCaT cells assessed as cell survival at 50 uM after 48 hrs by Hoechst 33342 staining based assay relative to control2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Mechanisms of action and structure-activity relationships of cytotoxic flavokawain derivatives.
AID1427259Cytotoxicity against human PC3 cells assessed as cell survival at 50 uM after 48 hrs by Hoechst 33342 staining based assay relative to control2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Mechanisms of action and structure-activity relationships of cytotoxic flavokawain derivatives.
AID1427256Cytotoxicity against human Caco2 cells assessed as cell survival at 50 uM after 48 hrs by Hoechst 33342 staining based assay relative to control2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Mechanisms of action and structure-activity relationships of cytotoxic flavokawain derivatives.
AID1427257Cytotoxicity against human MDA-MB-231 cells assessed as cell survival at 50 uM after 48 hrs by Hoechst 33342 staining based assay relative to control2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Mechanisms of action and structure-activity relationships of cytotoxic flavokawain derivatives.
AID315125Inhibition of IL1 production from human peripheral blood monocytes2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Synthesis and pharmacological activity of chalcones derived from 2,4,6-trimethoxyacetophenone in RAW 264.7 cells stimulated by LPS: quantitative structure-activity relationships.
AID1427255Cytotoxicity against human HuH7 cells assessed as cell survival at 50 uM after 48 hrs by Hoechst 33342 staining based assay relative to control2017Bioorganic & medicinal chemistry, 03-15, Volume: 25, Issue:6
Mechanisms of action and structure-activity relationships of cytotoxic flavokawain derivatives.
AID612698Antileishmanial activity against promastigotes form of Leishmania braziliensis MHOM/BR/75/M2904 at 50 uM after 72 hrs2011Bioorganic & medicinal chemistry, Aug-15, Volume: 19, Issue:16
Trimethoxy-chalcone derivatives inhibit growth of Leishmania braziliensis: synthesis, biological evaluation, molecular modeling and structure-activity relationship (SAR).
AID315137Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 24.90 uM by MTT assay2008Bioorganic & medicinal chemistry, Jan-15, Volume: 16, Issue:2
Synthesis and pharmacological activity of chalcones derived from 2,4,6-trimethoxyacetophenone in RAW 264.7 cells stimulated by LPS: quantitative structure-activity relationships.
AID86838In vitro antimitotic activity against HeLa cells after 6 hours exposure1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Chalcones: a new class of antimitotic agents.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (40.00)18.2507
2000's1 (20.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.87 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
n-(3-(aminomethyl)benzyl)acetamidine
N-(3-(aminomethyl)benzyl)acetamidine: structure in first source. N-[3-(aminomethyl)benzyl]acetamidine : An aralkylamine that is Nbenzylacetamidine substituted at position 3 on the benzene ring by an aminomethyl group. An inhibitor of nitric oxide synthase.		2.0410aralkylamine;
carboxamidine;
primary amino compound		angiogenesis inhibitor;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
geroprotector
pentamidine
Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.		2.0610aromatic ether;
carboxamidine;
diether		anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic
colchicine
(S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.		1.9710alkaloid;
colchicine		anti-inflammatory agent;
gout suppressant;
mutagen
vinblastine
[no description available]		1.9710
cyc 202
seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.		2.15102,6-diaminopurinesantiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
chalcone
trans-chalcone : The trans-isomer of chalcone.		2.3820chalconeEC 3.2.1.1 (alpha-amylase) inhibitor
2'-hydroxychalcone
2'-hydroxychalcone : A member of the class of chalcones that is trans-chalcone substituted by a hydroxy group at position 2'.		1.9810chalcones;
phenols		anti-inflammatory agent
4'-methoxychalcone
4'-methoxychalcone: RN given refers to compound with no isomeric designation		1.9810chalcones
amphotericin b
Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.		2.0610antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
4'-hydroxychalcone
4'-hydroxychalcone: inhibits TNFalpha-induced NF-κB activation; structure in first source. 4'-hydroxychalcone : A member of the class of chalcones that is trans-chalcone substituted by a hydroxy group at position 4'.		1.9810chalcones;
phenols		anti-inflammatory agent;
antineoplastic agent
2',6'-dimethoxychalcone
[no description available]		1.9810aromatic compound
flavokawain a
flavokawain A: from kava extract, induces apoptosis in bladder cancer cells; structure in first source		2.1510chalcones
flavokawain b
flavokawain B: from Piper methysticum Forst (Kava Kava) roots; structure in first source. flavokawain B : A member of the class of chalcones that consists of trans-chalcone substituted by hydroxy group at positions 2' and methoxy groups at positions 4' and 6'. Isolated from Piper methysticum and Piper rusbyi, it exhibits antileishmanial, anti-inflammatory and antineoplastic activities.		2.1510chalcones;
dimethoxybenzene;
phenols		anti-inflammatory agent;
antileishmanial agent;
antineoplastic agent;
apoptosis inducer;
metabolite
mdl 27048
MDL 27048: structure given in first source; powerful & reversible microtubule inhibitor		1.9710
pi103
PI103: pyridofuropyrimidine antineoplastic; a potent inhibitor of class I phosphatidylinositide 3-kinases (PI3K); structure in first soruce		2.1510aromatic amine;
morpholines;
organic heterotricyclic compound;
phenols;
tertiary amino compound		antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
Endotoxin Shock
[description not available]		01.9810
Shock, Septic
Sepsis associated with HYPOTENSION or hypoperfusion despite adequate fluid resuscitation. Perfusion abnormalities may include but are not limited to LACTIC ACIDOSIS; OLIGURIA; or acute alteration in mental status.		01.9810